(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: **0 327 283 B1**

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **18.08.93** (51) Int. Cl.5: **A61K 39/395**, C12P 21/00

(21) Application number: **89300872.2**

(22) Date of filing: **30.01.89**

Consolidated with 89902151.3/0397764
(European application No./publication No.) by
decision dated 17.06.92.

(54) Method of reducing immunoglobulin E responses.

(30) Priority: **02.02.88 US 151413**

(43) Date of publication of application:
09.08.89 Bulletin 89/32

(45) Publication of the grant of the patent:
18.08.93 Bulletin 93/33

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(56) References cited:
EP-A- 0 254 767
EP-A- 0 255 547

PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCE USA, vol. 83, December 1986; F.D.FINKELMAN et al., pp. 9675-9678*

JOURNAL OF IMMUNOLOGY, vol. 141, 01 October 1988; F.D.FINKELMAN et al., pp. 2335-2341*

NATURE, vol. 315, 23 May 1985; J.OHARA et al., pp. 333-335*

(73) Proprietor: **Schering Biotech Corporation**
901 California Avenue
Palo Alto California 94304-1104(US)

(72) Inventor: **Coffman, Robert L.**
239 Echo Lane
Portolo Valley, CA 94025(US)
Inventor: **de Vries, Jan Egbert**
6C Chemin du Trouyllat
F-69130 Ecully(FR)

(74) Representative: **Ritter, Stephen David et al**
Mathys & Squire 10 Fleet Street
London EC4Y 1AY (GB)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Rank Xerox (UK) Business Services
(3.10/3.6/3.3.1)

Description

The invention relates generally to a method for treating immune disease associated with excessive production of immunoglobulin E (IgE) and, more particularly, to a method of reducing IgE production by inhibiting the action of interleukin-4.

As far as can be determined, the main physiological function of IgE-mediated responses is to combat parasites. The response can be divided into five phases: an IgE-bearing B cell is stimulated to respond to an antigen (phase 1) and activated to secrete IgE antibodies (phase 2); the produced antibodies bind to mast cells and basophils in tissue (phase 3, antibody fixation), interaction of antigen with cell-bound IgE activates these cells, and causes the release of chemical mediators stored in their granules (phase 4, degranulation); and finally, the mediators induce a complex tissue response aimed at the elimination of nonmicrobial parasites from the body (phase 5). Part of this defense mechanism is an attack on the tissue that harbors the parasite--that is, on self. To excise a parasite from a tissue without damaging the rest of the body is an extraordinarily delicate act. The mediators released by activated mast cells and basophils can cause considerable harm, even death, if released at an inappropriate time or if directed at an inappropriate target. The IgE response must be closely controlled and quickly attenuated after its goal has been achieved. As long as this control is functioning there is no danger that healthy parts of the body will be damaged, but, should the controls fail, the beneficial reaction will turn into a harmful one. About 90 percent of all humans have no difficulty in using their IgE only for defensive purposes; but the remaining unlucky 10 percent carry a genetic defect of the control mechanism that permits the stimulation of IgE responses by antigens that have nothing to do with parasites. At first it was thought that this defect was limited only to humans, but similar defects were discovered later in several other mammals. The inappropriately stimulated IgE responses cause a plethora of diverse diseases, grouped under the name allergy or atopy; see Klein, Immunology: The Science of Self-Nonself Discrimination (John Wiley & Sons, New York, 1982).

Currently glucocorticoid steroids are the most effective drugs for treating allergic diseases. However, prolonged steroid treatment is associated with many deleterious side effects: Goodman and Gilman, The Pharmacological Basis of Therapeutics, 6th Ed. (MacMillan Publishing Company, New York, 1980). Consequently, the availability of alternative approaches to the treatment of immune disorders associated with excessive IgE production could have important clinical utility.

The invention therefore provides a pharmaceutical composition for reducing an immunoglobulin E response in a person comprising an effective amount of an antagonist to human interleukin-4 and a pharmaceutically acceptable carrier. The invention also provides the use of an antagonist to human interleukin-4 for the preparation of a therapeutic composition useful in reducing an immunoglobulin E response.

The antagonist to human interleukin-4 is preferably a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, a fragment of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, or a binding composition comprising the heavy chain variable region and light chain variable region of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4.

The invention is based on the discovery that IL-4 increases the production of IgE in humans. The method of the invention therefore comprises administering to a patient an effective, or disease-ameliorating amount, of an antagonist to human IL-4.

Finkelman et al. in Proc. Natl. Acad. Sci. USA, vol. 83, Dec. 1986, pp. 9675-9678, report how administration to mice of a monoclonal antibody to mouse BSF-1, i.e. mouse IL-4, reduces polyclonal IgE production in mice. However, there is relatively little homology (about 40%) between mouse IL-4 and human IL-4, and there is no reason to expect a carryover of this activity to human IL-4 in humans.

Preferably, the antagonists of the invention are derived from antibodies specific for human IL-4. More preferably, the antagonists of the invention comprise fragments or binding compositions specific for IL-4.

Antibodies comprise an assembly of polypeptide chains linked together by disulfide bridges. Two major polypeptide chains, referred to as the light chain and the heavy chain, make up all major structural classes (isotypes) of antibody. Both heavy chains and light chains are further divided into subregions referred to as variable regions and constant regions. Heavy chains comprise a single variable region and three different constant regions, and light chains comprise a single variable region (different from that of the heavy chain) and a single constant region (different from those of the heavy chain). The variable regions of the heavy chain and light chain are responsible for the antibody's binding specificity.

As used herein, the term "heavy chain variable region" means a polypeptide (1) which is from 110 to 125 amino acids in length (the number starting from the heavy chain's N-terminal amino acid), and

(2) whose amino acid sequence corresponds to that of a heavy chain of a monoclonal antibody of the invention. Likewise, the term "light chain variable region" means a polypeptide (1) which is from 95 to 115 amino acids in length (the numbering starting from the light chain's N-terminal amino acid), and (2) whose amino acid sequence corresponds to that of a light chain of a monoclonal antibody of the invention.

As used herein the term "monoclonal antibody" refers to homogenous populations of immunoglobulin which are capable of specifically binding to human IL-4.

As used herein the term "binding composition" means a composition comprising two polypeptide chains (1) which, when operationally associated, assume a conformation having high binding affinity for human interleukin-4, and (2) which are derived from a hybridoma producing monoclonal antibodies specific for human interleukin-4. The term "operationally associated" is meant to indicate that the two polypeptide chains can be positioned relative to one another for binding by a variety of means, including association in a native antibody fragment, such as Fab or Fv, or by way of genetically engineered cysteine-containing peptide linkers at the carboxyl termini. Normally, the two polypeptide chains correspond to the light chain variable region and heavy chain variable region of a monoclonal antibody specific for human interleukin-4.

Preferably, antagonists of the invention are derived from monoclonal antibodies specific for human IL-4. Monoclonal antibodies capable of blocking IgE-enhancing activity of IL-4 are selected in standard in vitro assays for IL-4 based on T cell proliferation; e.g. Yokota et al. Proc. Natl. Acad. Sci. USA, vol. 83, August 1986, pages 5894-5898. It has been observed in murine systems that all biological activities of IL-4 can be be blocked by a single monoclonal antibody. Thus, it is believed that all the activities are mediated by a single site, i.e. the receptor binding site, on the protein.

Hybridomas of the invention are produced by well-known techniques. Usually, the process involves the fusion of an immortalizing cell line with a B-lymphocyte which produces the desired antibody. Alternatively, non-fusion techniques for generating immortal antibody-producing cell lines are possible, and come within the purview of the present invention; e.g. virally induced transformation: Casali et al., "Human Monoclonals from Antigen-Specific Selection of B Lymphocytes and Transformation by EBV," Science, Vol. 234, pgs. 476-479 (1986). Immortalizing cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, or human origin. Most frequently, rat or mouse myeloma cell lines are employed as a matter of convenience and availability.

Techniques for obtaining the appropriate lymphocytes from mammals injected with the target antigen are well known. Generally, either peripheral blood lymphocytes (PBLs) are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. A non-human host mammal is injected with repeated dosages of the purified antigen, and the mammal is permitted to generate the desired antibody-producing cells before these are harvested for fusion with the immortalizing cell line. Techniques for fusion are also well known in the art, and in general involve mixing the cells with a fusing agent, such as polyethylene glycol. Hybridomas are selected by standard procedures, such as HAT selection. Human-human hybridomas are especially preferred. From among these hybridomas, those secreting the desired antibody are selected by assaying their culture medium by standard immunoassays, such as Western blotting, ELISA, RIA, or the like. Antibodies are recovered from the medium using standard protein purification techniques; e.g. Tijssen, Practice and Theory of Enzyme Immunoassays (Elsevier, Amsterdam, 1985). Many references are available for guidance in applying any of the above techniques; e.g. Kohler et al., Hybridoma Techniques (Cold Spring Harbor Laboratory, New York, (1980); Tijssen, Practice and Theory of Enzyme Immunoassays (Elsevier, Amsterdam, 1985); Campbell, Monoclonal Antibody Technology (Elsevier, Amsterdam, 1984); Hurrell, Monoclonal Hybridoma Antibodies: Techniques and Applications (CRC Press, Boca Raton, FL, 1982); and the like.

The use and generation of fragments of antibodies is also well known, e.g. Fab fragments: Tijssen, Practice and Theory of Enzyme Immunoassays (Elsevier, Amsterdam, 1985); and Fv fragments. Hochman et al., Biochemistry, Vol. 12, pgs. 1130-1135 (1973), Sharon et al., Biochemistry, Vol. 15, pgs 1591-1594 (1976), and Ehrlich et al., U.S. Patent 4,355,023; and antibody half-molecules: Auditore-Hargreaves, U.S. Patent 4,470,925. Moreover, such compounds and compositions of the invention can be used to construct bi-specific antibodies by known techniques; e.g., further fusions of hybridomas (i.e. to form so-called quadromas) -- see Reading, U.S. Patent 4,474,493; or chemical reassociation of half-molecules -- see Brennan et al., Science, Vol. 229, pgs. 81-83 (1985).

Hybridomas and monoclonal antibodies of the invention are produced against either glycosylated or unglycosylated versions of recombinantly-produced mature human interleukin-4. Generally, unglycosylated versions of human IL-4 are produced in E. coli and glycosylated versions are produced in mammalian cell hosts, e.g. CV1 or COS monkey

cells, mouse L cells, or the like. Recombinantly produced mature human IL-4 is produced by introducing an expression vector into a host cell using standard protocols; e.g. Maniatis et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, New York, 1982); Okayama and Berg, Mol. Cell. Biol., Vol 2, pgs 161-170 (1982) and Vol. 3, pgs. 280-289 (1983); Hamer, Genetic Engineering, Vol. 2, pgs. 83-100 (1980) and U.S. Patent 4,599,308; Kaufman et al., Mol. Cell. Biol., Vol. 2, pgs. 1304-1319 (1982); or the like.

Construction of bacterial or mammalian expression vectors is well known in the art, once the nucleotide sequence encoding a desired protein is known or otherwise available; e.g. DeBoer in U.S. Patent 4,551,433 discloses promoters for use in bacterial expression vectors; Goeddel et al. in U.S. Patent 4,601,980, and Riggs in U.S. Patent 4,431,739 disclose the production of mammalian proteins by E. coli expression systems; and Riggs (cited above), Ferretti et al., Proc. Natl. Acad. Sci., Vol. 83, pgs 599-603 (1986), Sproat et al., Nucleic Acids Research, Vol. 13, pgs. 2959-2977 (1985), and Mullenbach et al., J. Biol. Chem., Vol. 261, pgs. 719-722 (1986) disclose how to construct synthetic genes for expression in bacteria. Accordingly, these references are incorporated by reference. The amino acid sequence of mature human IL-4 is disclosed by Yokota et al. (cited above), and the cDNA encoding human IL-4 carried by the pcD vector described by Yokota et al. (cited above) is deposited with the American Type Culture Collection (ATCC), Rockville, MD, under accession number 67029. Many bacterial expression vectors and hosts are available commercially and through the ATCC. Preferably, human IL-4 for immunizing host animals is isolated from culture supernatants of COS, CV1, or mouse L cells which have been transiently transfected by the above-mentioned pcD vector.

Antibodies and antibody fragments characteristic of hybridomas of the invention can also be produced by recombinant means by extracting messenger RNA, constructing a cDNA library, and selecting clones which encode segments of the antibody molecule; e.g. Wall et al., Nucleic Acids Research, Vol. 5, pgs. 3113-3128 (1978); Zakut et al., Nucleic Acids Research, Vol. 8, pgs. 3591-3601 (1980); Cabilly et al., Proc. Natl. Acad. Sci., Vol. 81, pgs. 3273-3277 (1984); Boss et al., Nucleic Acids Research, Vol. 12, pgs. 3791-3806 (1984); Amster et al., Nucleic Acids Research, Vol. 8, pgs. 2055-2065 (1980); and Moore et al., U.S. Patent 4,642,334. In particular, such techniques can be used to produce interspecific monoclonal antibodies, wherein the binding region of one species is combined with a non-binding region of the antibody of another species to reduce immunogenicity; e.g. Liu et al., Proc. Natl. Acad. Sci., Vol. 84, pgs. 3439-3443 (1987).

Antagonists of the invention are administered as a pharmaceutical composition. Such compositions contain a therapeutic amount of at least one of the monoclonal antibodies of the invention, or fragments thereof, in a pharmaceutically effective carrier. A pharmaceutical carrier can be any compatible, non-toxic substance suitable for delivering the compositions of the invention to a patient. Sterile water, alcohol, fats, waxes, and inert solids may be included in a carrier. Pharmaceutically accepted adjuvants (e.g., buffering agents, dispersing agents) may also be incorporated into the pharmaceutical composition. Generally, compositions useful for parenteral administration of such drugs are well known, e.g. see Remington's Pharmaceutical Sciences, 15th Ed. (Mack Publishing Company, Easton, PA 1980). Alternatively, compositions of the invention may be introduced into a patient's body by implantable drug delivery system; e.g. see Urquhart et al., Ann. Rev. Pharmacol. Toxicol., Vol. 24, pgs. 199-236 (1984).

When the antagonists of the invention are derived from antibodies, they are normally administered parenterally, preferably intravenously. Since such protein- or peptide-antagonists may be immunogenic, they are preferably administered slowly, either by a conventional IV administration set or from a subcutaneous depot.

When administered parenterally, the antibodies or fragments will normally be formulated with a pharmaceutically acceptable parenteral vehicle in a unit dosage form suitable for injection (solution, suspension, emulsion). Such vehicles are inherently nontoxic and nontherapeutic. Examples of such vehicles are normal saline, Ringer's solution, dextrose solution, and Hank's solution. Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. A preferred vehicle is 5% dextrose/saline. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. The antibody is preferably formulated in purified form substantially free of aggregates and other proteins at concentrations of 5 to 30 mg/ml, preferably 10 to 20 mg/ml. For intravenous delivery, this may then be adjusted to a concentration in the range of 1 to 20 mg/ml.

Selecting an administration regimen for an antagonist depends on several factors, including the serum turnover rate of the antagonist, the serum level of IL-4 associated with the immune disorder, the immunogenicity of the antagonist, the accessibility of the target IL-4 (e.g. if non-serum IL-4 is to be blocked), the affinity of IL-4 to its receptor(s) relative to that of IL-4 to the antagonist, and the like. Preferably, an administration regimen maxi-

mizes the amount of antagonist delivered to the patient consistent with an acceptable level of side effects. Accordingly, the amount of antagonist delivered depends in part on the particular antagonist and the severity of the disease being treated. Guidance in selecting appropriate doses is found in the literature on therapeutic uses of antibodies; e.g. Bach et al., chapter 22, in Ferrone et al., eds., Handbook of Monoclonal Antibodies (Noges Publications, Park Ridge, NJ, 1985); and Russell, pgs. 303-357, and Smith et al., pgs. 365-389, in Haber et al., eds. Antibodies in Human Diagnosis and Therapy (Raven Press, New York, 1977). Preferably, the dose is in the range of 1-20 mg/kg per day, especially when the antagonist comprises monoclonal antibodies or Fab-sized fragments thereof (including binding compositions). More preferably the dose is in the range of 1-10 mg/kg per day.

The descriptions of the foregoing embodiments of the invention have been presented for purpose of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed. The embodiments were chosen and described in order to best explain the principles of the invention and its practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments. It is intended that the scope of the invention be defined by the claims appended hereto.

Applicants have deposited E. coli MC1061 carrying pcD-human-IL4 with the American Type Culture Collection, Rockville, MD, USA (ATCC), under accession number 67029. This deposit was made under the Budapest Treaty (1977) on the International Recognition of the Deposit of Micro-organisms for the purposes of Patent Procedure.

Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A pharmaceutical composition for reducing an immunoglobulin E response in humans comprising an effective amount of an antagonist to human interleukin-4 and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of Claim 1 wherein said antagonist to human interleukin-4 is selected from a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, a fragment of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, and a binding composition comprising the heavy chain variable region and light chain variable region of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4.

3. The pharmaceutical composition of Claim 2 wherein said fragment of said monoclonal antibody is an Fab fragment.

4. The pharmaceutical composition of Claim 2 wherein said monoclonal antibody is produced by a human-human hybridoma.

5. The pharmaceutical composition of Claim 4 wherein said fragment of said monoclonal antibody is an Fab fragment.

6. The pharmaceutical composition of Claim 2 wherein said composition is adapted for intravenous delivery of said antagonist at a concentration in the range of 1 to 20 mg/ml.

7. The pharmaceutical composition of Claim 6 wherein said composition is adapted for intravenous delivery of an amount of said antagonist in the range of about 1 to 20 mg/kg body weight of said individual per day.

8. Use of an antagonist to human interleukin-4 for the preparation of a therapeutic composition useful in reducing an immunoglobulin E response in humans.

9. Use as claimed in claim 8 wherein said antagonist to human interleukin-4 is selected from a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, a fragment of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, and a binding composition comprising the heavy chain variable region and light chain variable region of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4.

10. Use as claimed in claim 9 wherein said monoclonal antibody is an Fab fragment produced by a human-human hybridoma.

Claims for the following Contracting States : ES, GR

1. A method of producing a pharmaceutical composition for reducing an immunoglobulin E response in humans which comprises mixing an effective amount of an antagonist to human interleukin-4 and a pharmaceutically accept-

able carrier.

2. The method of Claim 1 wherein said antagonist to human interleukin-4 is selected from a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, a fragment of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, and a binding composition comprising the heavy chain variable region and light chain variable region of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4.

3. The method of Claim 2 wherein said fragment of said monoclonal antibody is an Fab fragment.

4. The method of Claim 2 wherein said monoclonal antibody is produced by a human-human hybridoma.

5. The method of Claim 4 wherein said fragment of said monoclonal antibody is an Fab fragment.

6. The method of Claim 2 wherein said composition is adapted for intravenous delivery of said antagonist at a concentration in the range of 1 to 20mg/ml.

7. The method of Claim 6 wherein said composition is adapted for intravenous delivery of an amount of said antagonist in the range of about 1 to 20mg/kg body weight of said individual per day.

8. Use of an antagonist to human interleukin-4 for the preparation of a therapeutic composition useful in reducing an immunoglobulin E response in humans.

9. Use as claimed in Claim 8 wherein said antagonist to human interleukin-4 is selected from a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4, a fragment of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleuking-4, and a binding composition comprising the heavy chain variable region and light chain variable region of a monoclonal antibody capable of blocking the immunoglobulin E enhancing activity of human interleukin-4.

10. Use as claimed in Claim 9 wherein said monoclonal antibody is an Fab fragment produced by a human-human hybridoma.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Pharmazeutische Zusammensetzung zur Verminderung einer Immunglobulin E Antwort beim Menschen, umfassend eine wirksamen Menge eines Antagonisten für humanes Interleukin-4 und einen pharmazeutisch annehmbaren Träger.

2. Pharmazeutische Zusammensetzung nach Anspruch 1, worin der Antagonist für humanes Interleukin-4 ausgewählt ist aus einem monoclonalen Antikörper, der befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren, einem Fragment eines monoclonalen Antikörpers, das befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren und einer bindenden Zusammensetzung, umfassend die schwere Kette der variablen Region und die leichte Kette der variablen Region eines monoclonalen Antikörpers, die befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren.

3. Pharmazeutische Zusammensetzung nach Anspruch 2, worin das Fragment des monoclonalen Antikörpers ein Fab-Fragment ist.

4. Pharmazeutische Zusammensetzung nach Anspruch 2, worin der monoclonale Antikörper durch ein Human-Human-Hybridom erzeugt ist.

5. Pharmazeutische Zusammensetzung nach Anspruch 4, worin das Fragment des monoclonalen Antikörpers ein Fab-Fragment ist.

6. Pharmazeutische Zusammensetzung nach Anspruch 2, worin die Zusammensetzung zur intravenösen Zuführung des Antagonisten bei einer Konzentration im Bereich von 1 bis 20 mg/ml geeignet ist.

7. Pharmazeutische Zusammensetzung nach Anspruch 6, worin die Zusammensetzung zur intravenösen Zuführung des Antagonisten in einer Menge im Bereich von etwa 1 bis 20 mg/kg Körpergewicht der Person pro Tag geeignet ist.

8. Verwendung eines Antagonisten für humanes Interleukin-4 für die Herstellung einer therapeu-

tischen Zusammensetzung, die für die Verminderung einer Immunglobulin E Antwort beim Menschen nützlich ist.

9. Verwendung nach Anspruch 8, worin der Antagonist für humanes Interleukin-4 ausgewählt ist aus einem monoclonalen Antikörper, der befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren, einem Fragment eines monoclonalen Antikörpers, das befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren und einer bindenden Zusammensetzung, umfassend die schwere Kette der variablen Region und die leichte Kette der variablen Region eines monoclonalen Antikörpers, die befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren.

10. Verwendung nach Anspruch 9, worin der monoclonale Antikörper ein Fab-Fragment ist, das von einem Human-Human-Hybridom erzeugt ist.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung zur Verminderung einer Immunglobulin E Antwort beim Menschen, umfassend das Mischen einer wirksamen Menge eines Antagonisten für humanes Interleukin-4 und einen pharmazeutisch annehmbaren Träger.

2. Verfahren nach Anspruch 1, worin der Antagonist für humanes Interleukin-4 ausgewählt ist aus einem monoclonalen Antikörper, der befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren, einem Fragment eines monoclonalen Antikörpers, das befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren und einer bindenden Zusammensetzung, umfassend die schwere Kette der variablen Region und die leichte Kette der variablen Region eines monoclonalen Antikörpers, die befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren.

3. Verfahren nach Anspruch 2, worin das Fragment des monoclonalen Antikörpers ein Fab-Fragment ist.

4. Verfahren nach Anspruch 2, worin der monoclonale Antikörper durch ein Human-Human-Hybridom erzeugt ist.

5. Verfahren nach Anspruch 4, worin das Fragment des monoclonalen Antikörpers ein Fab-Fragment ist.

6. Verfahren nach Anspruch 2, worin die Zusammensetzung zur intravenösen Zuführung des Antagonisten bei einer Konzentration im Bereich von 1 bis 20 mg/ml geeignet ist.

7. Verfahren nach Anspruch 6, worin die Zusammensetzung zur intravenösen Zuführung des Antagonisten in einer Menge im Bereich von etwa 1 bis 20 mg/kg Körpergewicht der Person pro Tag geeignet ist.

8. Verwendung eines Antagonisten für humanes Interleukin-4 für die Herstellung einer therapeutischen Zusammensetzung , die für die Verminderung einer Immunglobulin E Antwort beim Menschen nützlich ist.

9. Verwendung nach Anspruch 8, worin der Antagonist für humanes Interleukin-4 ausgewählt ist aus einem monoclonalen Antikörper, der befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren, einem Fragment eines monoclonalen Antikörpers, das befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren und einer bindenden Zusammensetzung, umfassend die schwere Kette der variablen Region und die leichte Kette der variablen Region eines monoclonalen Antikörpers, die befähigt ist, die Immunglobulin E verstärkende Aktivität des humanen Interleukin-4 zu blockieren.

10. Verwendung nach Anspruch 9, worin der monoclonale Antikörper ein Fab-Fragment ist, das von einem Human-Human-Hybridom erzeugt ist.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Composition pharmaceutique pour réduire une réponse à l'immunoglobuline E chez des êtres humains, comprenant une quantité efficace d'un antagoniste à l'interleukine-4 humaine et un support acceptable en pharmacie.

2. Composition pharmaceutique de la revendication 1, où ledit antagoniste à l'interleukine-4 humaine est choisi parmi un anticorps mono-

clonal capable de bloquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine, un fragment d'un anticorps monoclonal capable de bloquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine et une composition de liaison comprenant la région variable de la chaîne lourde et la région variable de la chaîne légère de l'anticorps monoclonal capable de bloquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine.

3. Composition pharmaceutique de la revendication 2, où ledit fragment dudit anticorps monoclonal est un fragment Fab.

4. Composition pharmaceutique de la revendication 2, où ledit anticorps monoclonal est produit par un hybridome humain-humain.

5. Composition pharmaceutique de la revendication 4, où ledit fragment dudit anticorps monoclonal est un fragment Fab.

6. Composition pharmaceutique de la revendication 2, où ladite composition est adaptée à une administration intraveineuse dudit antagoniste à une concentration comprise entre 1 et 20 mg/ml.

7. Composition pharmaceutique de la revendication 6, où ladite composition est adaptée à une administration intraveineuse d'une quantité dudit antagoniste comprise entre environ 1 et 20 mg/kg de poids corporel dudit individu par jour.

8. Utilisation d'un antagoniste à l'interleukine-4 humaine pour la préparation d'une composition thérapeutique utile pour réduire une réponse à l'immunoglobuline E chez les humains.

9. Utilisation selon la revendication 8, où ledit antagoniste à l'interleukine-4 humaine est choisi parmi un anticorps monoclonal capable de bloquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine, un fragment d'un anticorps monoclonal capable de provoquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine et une composition de liaison comprenant une région variable de la chaîne lourde et une région variable de la chaîne légère d'un anticorps monoclonal capable de bloquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine.

10. Utilisation selon la revendication 9, où ledit anticorps monoclonal est un fragment Fab produit par un hybrodome humain-humain.

Revendications pour les Etats contractants suivants : ES, GR

1. Méthode de production d'une composition pharmaceutique pour réduire une réponse à l'immunoglobuline E chez les humains, qui comprend le mélange d'une quantité efficace d'un antagoniste à l'interleukine-4 humaine et d'un support acceptable en pharmacie.

2. Méthode de la revendication 1, où ledit antagoniste à l'interleukine-4 humaine est choisi parmi un anticorps monoclonal capable de bloquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine, un fragment d'un anticorps monoclonal capable de bloquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine et une composition de liaison comprenant la région variable de la chaîne lourde et la région variable de la chaîne légère de l'anticorps monoclonal capable de bloquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine.

3. Méthode de la revendication 2, où ledit fragment dudit anticorps monoclonal est un fragment Fab.

4. Méthode de la revendication 2, où ledit anticorps monoclonal est produit par un hybridome humain-humain.

5. Méthode de la revendication 4, où ledit fragment dudit anticorps monoclonal est un fragment Fab.

6. Méthode de la revendication 2, où ladite composition est adaptée à une administration intraveineuse dudit antagoniste à une concentration comprise entre 1 et 20 mg/ml.

7. Méthode de la revendication 6, où ladite composition est adaptée à une administration intraveineuse d'une quantité dudit antagoniste comprise entre environ 1 et 20 mg/kg de poids corporel dudit individu par jour.

8. Utilisation d'un antagoniste à l'interleukine-4 humaine pour la préparation d'une composition thérapeutique utile pour réduire une réponse à l'immunoglobuline E chez les humains.

9. Utilisation selon la revendication 8, où ledit antagoniste à l'interleukine-4 humaine est choi-

si parmi un anticorps monoclonal capable de bloquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine, un fragment d'un anticorps monoclonal capable de provoquer l'activité d'amélioration de l'immunoglobuline E de l'interleukine-4 humaine et une composition de liaison comprenant une région variable de la chaîne lourde et une région variable de la chaîne légère d'un anticorps monoclonal de l'immunoglobuline E de l'interleukine-4 humaine.

10. Utilisation selon la revendication 9, iù ledit anticorps monoclonal est un fragment Fab produit par un hybridome humain-humain.

REGISTER ENTRY FOR EP0327283

European Application No EP89300872.2 filing date 30.01.1989

Priority claimed:
02.02.1988 in United States of America - doc: 151413

Designated States BE CH DE ES FR GB GR IT LI LU NL SE AT

Title METHOD OF REDUCING IMMUNOGLOBULIN E RESPONSES

Applicant/Proprietor
SCHERING BIOTECH CORPORATION, 901 California Avenue, Palo Alto California 94304-1104, United States of America [ADP No. 50326057001]

Inventors
ROBERT L. COFFMAN, 239 Echo Lane, Portola Valley, CA 94025, United States of America [ADP No. 58840414001]

JAN EGBERT DE VRIES, 6C, chemin du Trouyllat, F-69130 Ecully, France [ADP No. 57998684001]

Classified to
A61K C12P

Address for Service
MATHYS & SQUIRE, 10 Fleet Street, London, EC4Y 1AY, United Kingdom [ADP No. 00001081001]

EPO Representative
STEPHEN DAVID RITTER, Mathys & Squire 10 Fleet Street, London EC4Y 1AY, United Kingdom [ADP No. 50530237001]

Publication No EP0327283 dated 09.08.1989
Publication in English

Examination requested 22.01.1990

Patent Granted with effect from 18.08.1993 (Section 25(1)) with title METHOD OF REDUCING IMMUNOGLOBULIN E RESPONSES.

17.06.1992 Consolidated with 89902151.3/0397764 (European application No./publication No.) by decision dated 17.06.1992.
Entry Type 10.1 Staff ID. DG2 Auth ID. BACK

23.02.1993 MATHYS & SQUIRE, 10 Fleet Street, London, EC4Y 1AY, United Kingdom [ADP No. 00001081001]
registered as address for service
Entry Type 8.11 Staff ID. ER1 Auth ID. AA

19.07.1993 Notification from EPO of change of Inventor details from ROBERT L. COFFMAN, 239 Echo Lane, Portola Valley, CA 94025, United States of America [ADP No. 58840414001]

JAN EGBERT DE VRIES, 6C, chemin du Trouyllat, F-69130 Ecully, France [ADP No. 57998684001]
to
ROBERT L. COFFMAN, 239 Echo Lane, Portolo Valley, CA 94025, United States of America [ADP No. 61145967001]

JAN EGBERT DE VRIES, 6C Chemin du Trouyllat, F-69130 Ecully, France [ADP No. 61145975001]
Entry Type 25.14 Staff ID. RD06 Auth ID. EPT

24.06.1994 EPO: Opposition filed on 17.05.1994
Entry Type 25.1 Staff ID. RD06 Auth ID. EPT

05.01.1995 Notification of change of Address For Service address of
MATHYS & SQUIRE, 10 Fleet Street, London, EC4Y 1AY, United Kingdom [ADP No. 00001081001]
to
MATHYS & SQUIRE, 100 Grays Inn Road, LONDON, WC1X 8AL, United Kingdom [ADP No. 00001081001]
dated 12.12.1994. Written notification filed on GB2278511
Entry Type 7.3 Staff ID. AS1 Auth ID. EO

**** END OF REGISTER ENTRY ****

RENEWAL DETAILS

PUBLICATION NUMBER EP0327283

PROPRIETOR(S)

Schering Biotech Corporation, 901 California Avenue, Palo Alto California 94304-1104, United States of America

DATE FILED 30.01.1989

DATE GRANTED 18.08.1993

DATE NEXT RENEWAL DUE 30.01.1997

DATE NOT IN FORCE

DATE OF LAST RENEWAL 19.12.1995

YEAR OF LAST RENEWAL 08

STATUS PATENT IN FORCE

**** END OF REPORT ****